These drugs also activate GLP-1 receptors in the hypothalamus, which increases the release of anorexigenic peptides like pro-opiomelanocortin while reducing the release of orexigenic peptides like neuropeptide Y and agouti-related peptide
Mol Psychiatry 27:50495061 Bot M, Milaneschi Y, Al-Shehri T, Amin N, Garmaeva S, Onderwater GLJ, Pool R, Thesing CS, Vijfhuizen LS, Vogelzangs N, Arts ICW, Demirkan A, van Duijn C, van Greevenbroek M, van der Kallen CJH, Kohler S, Ligthart L, van den Maagdenberg A, Mook-Kanamori DO, de Mutsert R, Tiemeier H, Schram MT, Stehouwer CDA, Terwindt GM, Willems van Dijk K, Fu J, Zhernakova A, Beekman M, Slagboom PE, Boomsma DI, Penninx B, Consortium B-NM (2020) Metabolomics profile in depression: a pooled analysis of 230 metabolic markers in 5283 cases with depression and 10,145 controls
lawmakers passed legislation to raise the federal debt ceiling on multiple occasions, ratings agencies have lowered or threatened to lower the long-term sovereign credit rating on the U.S
TA875: Semaglutide for managing overweight and obesity Recommendations
